Research
Truist Downgrades Evolent Health to Hold From Buy, Keeps $7 Price Target, Cites Recent Share Price Strength, Medicaid Headwind
Evolent Health (EVH) has an average rating of buy and mean price target of $5.88, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$EVH
